Alterity Therapeutics (ATHE) Competitors $4.40 -0.19 (-4.14%) Closing price 04:00 PM EasternExtended Trading$4.58 +0.18 (+4.18%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATHE vs. NLTX, SLS, ALTS, LFVN, PRME, ACOG, ACRS, ALMS, SPRO, and MOLNShould you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include Neoleukin Therapeutics (NLTX), SELLAS Life Sciences Group (SLS), Janone (ALTS), LifeVantage (LFVN), Prime Medicine (PRME), Alpha Cognition (ACOG), Aclaris Therapeutics (ACRS), Alumis (ALMS), Spero Therapeutics (SPRO), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry. Alterity Therapeutics vs. Its Competitors Neoleukin Therapeutics SELLAS Life Sciences Group Janone LifeVantage Prime Medicine Alpha Cognition Aclaris Therapeutics Alumis Spero Therapeutics Molecular Partners Neoleukin Therapeutics (NASDAQ:NLTX) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Do analysts rate NLTX or ATHE? Alterity Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 172.73%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Neoleukin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Alterity Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has stronger valuation & earnings, NLTX or ATHE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeoleukin TherapeuticsN/AN/A-$57.56M-$3.11-6.56Alterity TherapeuticsN/AN/A-$12.54MN/AN/A Does the MarketBeat Community believe in NLTX or ATHE? Neoleukin Therapeutics received 45 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. However, 62.50% of users gave Alterity Therapeutics an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote. CompanyUnderperformOutperformNeoleukin TherapeuticsOutperform Votes5045.87% Underperform Votes5954.13% Alterity TherapeuticsOutperform Votes562.50% Underperform Votes337.50% Which has more risk and volatility, NLTX or ATHE? Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the S&P 500. Do institutionals and insiders hold more shares of NLTX or ATHE? 52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer NLTX or ATHE? In the previous week, Neoleukin Therapeutics and Neoleukin Therapeutics both had 1 articles in the media. Alterity Therapeutics' average media sentiment score of 1.89 beat Neoleukin Therapeutics' score of 0.00 indicating that Alterity Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Neoleukin Therapeutics Neutral Alterity Therapeutics Very Positive Is NLTX or ATHE more profitable? Alterity Therapeutics' return on equity of 0.00% beat Neoleukin Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neoleukin TherapeuticsN/A -37.22% -30.91% Alterity Therapeutics N/A N/A N/A SummaryAlterity Therapeutics beats Neoleukin Therapeutics on 9 of the 12 factors compared between the two stocks. Get Alterity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATHE vs. The Competition Export to ExcelMetricAlterity TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.02M$6.88B$5.58B$8.50BDividend YieldN/A2.53%5.28%4.17%P/E RatioN/A8.5527.1919.64Price / SalesN/A262.61408.78152.17Price / CashN/A65.8538.3234.64Price / Book4.236.536.974.60Net Income-$12.54M$143.48M$3.23B$248.06M7 Day Performance-6.98%0.20%-0.88%-1.02%1 Month Performance6.02%10.93%7.81%3.51%1 Year Performance132.80%2.46%31.53%12.68% Alterity Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATHEAlterity Therapeutics2.1269 of 5 stars$4.40-4.1%$12.00+172.7%+136.6%$39.02MN/A0.0010Positive NewsNLTXNeoleukin TherapeuticsN/A$17.01-9.2%N/A-43.7%$159.86MN/A-5.4790Gap UpHigh Trading VolumeSLSSELLAS Life Sciences Group0.3152 of 5 stars$1.58-7.6%N/A+13.8%$157.65M$1M-2.2910Short Interest ↑High Trading VolumeALTSJanoneN/A$9.01-3.2%N/AN/A$157.27M$18.05M0.00170Short Interest ↑Gap DownLFVNLifeVantage4.0151 of 5 stars$12.45-4.6%$30.50+145.0%+72.3%$156.72M$222.35M22.23260Positive NewsPRMEPrime Medicine3.8948 of 5 stars$1.19+0.8%$10.08+747.3%-81.0%$156.24M$3.85M-0.58234Positive NewsACOGAlpha Cognition1.7656 of 5 stars$9.74+4.4%$20.00+105.3%N/A$156.04M$2.93M-3.80N/ANews CoverageACRSAclaris Therapeutics2.6786 of 5 stars$1.44-1.4%$9.71+574.6%+33.0%$155.93M$17.78M-2.77100ALMSAlumis2.8633 of 5 stars$3.29-6.0%$24.86+655.5%N/A$155.36M$17.39M0.00N/APositive NewsUpcoming EarningsAnalyst UpgradeAnalyst RevisionHigh Trading VolumeSPROSpero Therapeutics3.8521 of 5 stars$2.74+9.6%$5.00+82.5%+102.1%$153.20M$28.30M39.15150Positive NewsShort Interest ↑Gap DownHigh Trading VolumeMOLNMolecular Partners2.8717 of 5 stars$3.79-0.7%$12.00+217.0%-32.8%$152.82M$2.23M-1.76180 Related Companies and Tools Related Companies NLTX Competitors SLS Competitors ALTS Competitors LFVN Competitors PRME Competitors ACOG Competitors ACRS Competitors ALMS Competitors SPRO Competitors MOLN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATHE) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATHE Stock Free ATHE Stock Alerts